Ladies and gentlemen, welcome to BWX Technologies' third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mood. Following the company's prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time. I would now like to turn the call over to our host, Chase Jacobson, BWXT's Vice President of Investor Relations. Please go ahead.

Thank you. Good evening, and welcome to today's and Mike Fitzgerald, Senior Vice President and CFO. On today's call, we'll reference the third quarter 2025 earnings presentation that is available on the Investor Section of the BWSC website. We will also discuss certain matters that constitute forward-looking statements. These statements involve risks and uncertainties, including those described in the safe harbor provisions found in the investor materials and the company's SEC filings. We will frequently discuss non-GAAP financial measures, which are reconciled to GAAP measures in the appendix of the Irving's presentation that can be found on the Investor's section of the BWXT website. I would now like to turn the call over to Rex.

Thank you, Chase, and good evening to all of you. I'm excited to report another strong quarter for BWXT, showcasing the effectiveness of our battle plan strategy and our leading position in nuclear solutions for the global security, clean energy, and medical end markets, all of which are enjoying unprecedented demand. Third quarter financial results exceeded our expectations, driven by focused execution and revenue growth in both government and commercial operations. We delivered 12% organic revenue growth, and roughly 20% adjusted EBITDA and earnings for shared growth alongside robust free cash flow generation. Book the bill was a stout 2.6 this quarter, driven by large multi-year national security contracts for the production of defense fuels and high-purity depleted uranium in our special materials line of business. This led to a total backlog of $7.4 billion, up 23% from last quarter and up 119% year-over-year. Our year-to-date financial results, deep backlog, and unprecedented in-market demand position us to enter 2026 from a position of financial strength. Our preliminary 2026 outlook calls for another year of record financial results with a posture to exceed our medium-term financial targets, turning segment results and market outlook. Government operations revenue was up 10% and adjusted EBITDA was up 1%, both ahead of expectations. In the naval propulsion business, our teams are intensely focused on meeting delivery commitments for submarine and aircraft carrier programs and driving operational excellence. In addition to traditional process optimization strategies, we are finding new ways to leverage artificial intelligence and advanced manufacturing to drive efficiencies around quality control and workflow in our facilities that will lead to improved productivity, throughput, and margin performance. Technical services is on a growth trajectory powered by a wind streak that unfolded over the last several years. Our team began transition for the Strategic Petroleum Reserve M&O contract in early October. And the BWXC-led joint venture, which includes Conetrix, is in the preferred bidder period, which is the transition period for management and operations of the Canadian nuclear laboratories. We expect to assume full operational control before the end of the year. In micro-reactors and advanced nuclear technologies, the market is evolving positively. We are currently manufacturing the reactor core for Pele, which is on track for delivery in 2027. Related to Pele, last month, the Army announced the Janus program, which aims to deploy a nuclear reactor on a military installation no later than September 2028, building on lessons learned for Project Pele. But BWXT's qualifications should be a differentiator for JANIS and other important national security projects that are within our cost and capital risk tolerances. During the quarter, we announced a collaboration with Kairos Power to commercially optimize Trisil nuclear fuel production. We are excited to have a partner that is aligned with Google. BWXT is currently producing trisyl fuel for Project Pele and a variety of other customers and will continue to evaluate options to enter the commercial market on a larger scale as the demand for advanced reactors grows. Lastly, over the last several quarters, we pointed to our special materials business line having some of the most exciting growth opportunities within the company. I'm pleased to say two of these opportunities, both within the NSA, materialized during the quarter. First, we were selected for the defense fuels contract, valued at $1.5 billion, to establish a domestic uranium enrichment capability for defense purposes. We booked the first task order under the contract and are building a centrifuge manufacturing development facility in Oak Ridge, Tennessee. Over the next several years, our focus will be on centrifuge manufacturing and designing and licensing a plant for defense uranium originals. Second, we were awarded a $1.6 billion 10-year contract to supply high-purity depleted uranium to the NMSA. This is a direct result of our foray into special materials and our deliberate strategy of expanding into the depleted uranium assay through the AOT acquisition. Under this contract, we will build a manufacturing plant adjacent to our existing facility in Jonesboro, Tennessee, capable of producing up to 300 metric tons of high-purity depleted uranium per year that will be used for multiple defense purposes. These are both exciting long-term projects for BWXT, not only for the revenue growth, but also the demonstration of trust our customers put in BWXT to execute on mission-critical, national security programs. Turning now to commercial operations, reported revenue grew 122%, and organic revenue grew 38% year-over-year, driven by the Conetrix acquisition, strong growth in commercial nuclear power, and medical isotopes. BWXT medical revenue grew double digits, driven by PET and other diagnostic product lines for which the outlook remains favorable. We expect this trend, along with the increasing therapeutic isotope sales for clinical trials, to support continued revenue growth in 2026. Consistent with our commentary last quarter, the TAT99 development is progressing nicely and is on track for an FDA submittal in the near future. In the therapeutics market, Connectrix commissioned four new electromagnetic isotope separator units that increase production capacity of dutervium-176, the precursor material for lutetium-177, to over 500 grams annually. This expansion reinforces our role as a global supplier of highly enriched, stable isotopes needed for cancer radiotherapy. Turning now to commercial power, where demand is very strong, and our opportunity set is expanding across various geographies and with many of the leading reactor technology OEM providers. In the can-do market, we have a deep backlog of heavy nuclear components supporting life extensions in Canada, including the 48 state generators for the Fickering life extension, which are driving significant revenue growth this year. Beyond that, BWXT and Conetrix are tracking opportunities for international can-do life extensions. The Canadian new builds we have discussed in the past, other large-scale opportunities, including the Westinghouse AP1000, and multiple SMR projects. In the SMR sector, we are a key partner with the majority of leading technology providers in this rapidly expanding market. To this point, we recently signed a contract with Rolls-Royce to design steam generators for its SMR, along with an MOU for the manufacturing phase, highlighting the power of our merchant supplier position in the market. With that, I will now turn the call over to Mike.

Thanks, Rex, and good evening, everyone. I'll begin with total company financial highlights on slide four of the earnings presentation. Third quarter revenue was $866 million, up 29%, driven by both segments. Excluding contributions from acquisitions, organic revenue was up 12%. Adjusted EBITDA was $151 million, up 19% year-over-year, driven by robust double-digit growth in commercial operations, a modest increase in government operations, and lower corporate expense. Adjusted earnings per share were $1, up 20%, driven by strong operating performance. Non-operating items were neutral on a net basis. Our adjusted effective tax rate in the quarter was 23.6%, and we continue to expect a tax rate of approximately 21% for the year. In 2026, given a greater percentage of international earnings following the Conetrics acquisition, we expect our tax rate to be slightly higher year over year. Our free cash flow was $95 million, driven by solid earnings performance and timing of cash receipts from major awards. We anticipate free cash flow in 2025 to be approximately $285 million, the high end of our previous outlook range. Capital expenditures were $48 million in the quarter and $114 million year-to-date. We anticipate full-year CapEx to be approximately 6% of sales, indicating an increase in the fourth quarter due to timing of spend on growth initiatives, including capacity expansion for commercial nuclear and a number of smaller projects in our government business. In 2026, we expect CapEx to remain at 5.5% to 6% of sales, supportive of our longer-term growth output. Moving now to the segment results on slide. More revenue was up 10%, driven by naval propulsion, long and bleed material procurement, special materials, and a roughly 3% contribution from the AOT acquisition. partially offset by a decline in microreactor volume. Adjusted EBITDA of $118 million was up modestly compared to last year, resulting in adjusted EBITDA margin of 19.2%. We expect government operations revenue to be up mid-single digits organically in 2025, plus just over a 2% contribution from the AOT acquisition, slightly ahead of our previous outlook, and we continue to expect adjusted EBITDA margin of approximately 20.5%. Turning to commercial operations, revenue was up a robust 122%, driven by contributions from the Conetrix acquisition. Organic revenue growth was 38%, driven by strong year-over-year growth in our commercial power business and double-digit growth in medical. The EBITDA in the segment was $36 million, up 163%. This results in adjusted EBITDA margin of 14.2%, a nice improvement compared to our first half results and up from the 11.9% in the same quarter last year. Margin expansion was driven by solid operational performance and more favorable mix compared to recent periods. We now anticipate 2025 commercial revenue to be up approximately 60% compared to last year, driven by high-teams organic growth and contribution from Conetrix, which is performing slightly ahead of our expectations since the closing of the acquisition in May. We expect segment-adjusted EBITDA margin to be approximately 13.5%, the low end of our previous range, due to the timing of the recovery of higher material procurement costs which have hugely impacted our results in the first half of the year. Turning to our consolidated guidance for the remainder of 2025 and our preliminary outlook for 2026, in 2025 we anticipate adjusted EBITDA to be approximately $570 million, the midpoint of our previous range. However, we now expect adjusted earnings per share to be $3.75 to $3.80, up $7.5 at the midpoint, given the benefit from non-operating items, including foreign currency gains and slightly lower interest expense. Looking to 2026, we anticipate another year of strong financial performance with low double-digit to low-teams adjusted EBITDA growth, yielding high single-digit to low double-digit adjusted earnings per share growth, given modest, non-operating headwinds. This should lead to another year of solid, although near-term working capital investments related to the significant growth in our flat display. In our segments, government operations revenue is expected to grow in the mid-teens, led by growth in special materials and supported by higher revenue in naval propulsion and micro-reactors. Of note, the Defense Fuels Program and HPDU will account for over half of the segment's growth in 2026, essentially customer-funded CAPEX, to build the unique infrastructure required for these programs, meaning they are expected to have a low average margin in the first phases compared to the rest of our such. We anticipate government operations adjusted EBITDA to grow in the high single-digit percentage range compared to 2025, ahead of our medium-term outlook for mid-single-digit growth in this segment. In commercial operations, we anticipate another year of robust revenue performance with low double-digit organic revenue and growth plus contribution from Conetrix. We anticipate adjusted EBITDA growth to outperform revenue growth driven by better margins due to the favorable mix and solid execution. Overall, we had a strong quarter, and we are well-positioned for another year of record financial results. Our backlog is robust. We have good visibility into the future, and we remain focused on driving improved margin performance and cash generation in our business. With that, I will turn it back to Rex for closing remarks.

Thanks, Mike. It is an exciting time for BWXT. The secular trends of decarbonization, electrification, and data center power demand, combined with an increasing appetite for nuclear solutions in the national security space, are meaningful tailwinds to BWXT. We are proud of our strong market position and the customer trust we have earned, built upon the expertise of our workforce, our differentiated infrastructure and credentials, and our strategic, organic, and inorganic investments. We are winning in our core businesses and expanding into new and exciting areas. During this period of exceptional growth, we are doubling down on operational excellence focus and expanding its application across the entire BWXT inner profits. We are driving further process improvements and increasing the use of industrial automation and artificial intelligence to optimize cost structure, product quality, and cash generation to maintain our winning position and drive shareholder value. And with that, we look forward to taking your questions.

Thank you. We will now begin the question and answer session. If you have dialed in and would like to ask a question, please press star 1 on your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star 1 again. If you are called upon to ask your question and are listening via speakerphone or device, please pick up your handset to ensure that your phone is not on mute when asking your question. We do request for today's session that you please limit to one question and one follow-up question only. Thank you. First question comes from the line of Pete Skabitsky with Alembic Global. Your line is open.

Good evening, guys. Nice quarter. um i guess for for anyone i guess um you know certainly on on an absolute basis this is one of the bigger um revenue beats of consensus that you guys have ever had i think so just wonder if you could clarify did you book any uh revenue on the two new contracts in the quarter i don't want into backlog but did you book any actual revenue on those two new ones and then just just kind of the modest full year sales guidance increase implies a a fourth quarter that will be down pretty sharply sequentially. So I'm wondering if you could explain that also. I don't know if there's some conservatism or something else. I'll stop there.

Yeah, thanks, Pete. So as it relates to the new contracts, very, very modest contribution, so not a big driver here. One of the things I think that you're seeing a little bit, and we've seen this trend this year in the second and third quarter, is the seasonality around some of our large material procurements. If you remember, what we've discussed in the past is as we enter into our pricing arrangements, we ultimately will work to get some of those long-lead material procurements done as quickly as possible to lock in pricing. And so we've been working to try to do that in the second and third quarter. We were able to accomplish that a little bit earlier this quarter in comparison to when we had originally forecasted it in the fourth quarter. So that is why you're seeing a large feat this quarter and ultimately a little bit of seasonality in the fourth quarter just as some of those material procurements have shifted to the right. I would say outside of that, we're seeing really strong performance in the shops, and we're continuing to see them outperform both on our government ops and our commercial ops segment, and so we're very encouraged by that and highly focused on driving continued operational excellence initiatives within the factories.

okay just one last one for me maybe for rex hey rex on the new janus program um it seems like this is supposed to be kind of a coco arrangement which i know you guys typically don't like to actually operate reactors in in the field so i'm wondering kind of what the approach is going to be for bwxt here and maybe it's just a simple team agreement is all that's needed but was curious as

your thoughts on that. Yeah, hi, Pete. We certainly do intend to compete for that Janus program. It's very interesting. The government's obviously looking at putting a number of reactors at a number of different sites, and I think they'll pick at least two contract teams for that. Yeah, we typically don't own and operate reactors. You know, that's normally the job of the nuclear utility, so it'll be a matter of finding the right teammates to go after that opportunity, but we'll do that, and we'll go in and compete hard for it. Got it. Thanks so much, guys. Thank you.

Our next question comes from the line of Robert Labick with CJS Securities. You're Lenny Sullivan.

Hi, this is Will on for Bob. With six months or so under your belt now, what are the key takeaways from the Conetrix acquisition, and what are some of the new market and revenue synergy opportunities?

Well, as I said on the call, Conetrix is outperforming so far. In fact, you know, I might speak more broadly and just say the two acquisitions that we did this year, the Jonesboro acquisition, AOT, and the Conetrix acquisition are both outperforming. And I think, frankly, we created a lot of value there. We bought both of those businesses well within our multiples, and both of them are doing quite well for us. For Conetrix itself, the outperformance relates to the transmission and distribution business, which is growing very smartly right now because of two things going on there. One is the aging infrastructure requires a lot of testing, so we're doing that. And then we've got a nice business in offshore wind cable testing, particularly focused in Europe. So we're seeing outsized growth there. The life extension programs at the Pickering plant are creating a lot of opportunities that Conetrix is well-suited for, so we're attacking that one. And then finally, you know, we're seeing some business, sizable business, around licensing support to the Canadian nuclear utilities for the new-built large projects, large reactor projects in that market. And I find that encouraging from multiple perspectives, obviously for Conetrix itself. But I think that demonstrates the seriousness of the nuclear utilities to proceed with their plans for large nuclear reactors. So, you know, a lot of goodness in the Conetrix business, and it's a really great match for BWXT. I might add that, by the way, that medical business of theirs is doing very nice, and there's a lot of talent in that part of the business, which has been helpful and synergistic to BWXT Medical.

Thank you. Just one more. With the exponential increase in the focus on energy production and security, where are the biggest and nearest-term opportunities for BWX to participate in the growth in nuclear energy, and how are you prioritizing investment into so many opportunities?

Yeah, I'd say we see demand everywhere. We see it on the commercial side of the business. We see it on the government side of the business. If you're speaking to commercial power in particular, I'd say the opportunities in order are kind of, you know, small modular reactors everywhere. And you know that we face the market as an merchant supplier, and we participate on the X300. We participate on the TerraPower Natrium reactor. We did a deal with Rolls-Royce, so we're supporting that reactor in steam generator design and ultimately manufacturing. And the geography is, you know, Canada, U.S., Europe, and Poland and the U.K. and other places. So that one is super interesting to us. I do expect to see SMR announcements in the U.S. in the fairly near future. I'd say the large reactor opportunity is expressing pretty strongly based on what I just said about the plans in Canada. I think they'll build at least eight, you know, can-do derivative large reactors at Wesleyville and at the Bruce site. And then obviously the Westinghouse announcement for $80 billion worth of reactors in the U.S. is, I think, quite a positive sign for the industry as it relates to capacity and the need for that. We're actively bidding on AP1000 components kind of every day. So that's in the commercial side of it. Now, Pete mentioned the Janus program, which is a, you know, kind of a quasi-commercial program because it's contractor-operated facilities for U.S. military sites. So that one's interesting in itself. And, of course, we see commercial outlets for TRISO, growth in nuclear medicine. So it's everywhere.

Thank you. Welcome.

Next question comes from the line of Peter Arment with Beard. You're Lenny Chauvin.

Hey, good afternoon, Rex. Mike, Chase, nice results. And can you, Rex, on the two large contracts that you booked in the quarter, the uranium enrichment and then the depleted uranium awards, I think Mike mentioned that there's just going to be some government-funded CapEx to help stand some of that up. But how does the revenue kind of cadence roll out when both of those programs kick off? And I guess related to that, Mike, you said it would probably initially come in some lower margins. Just how long of a period does that last? Thanks.

Yeah. So for both of those contracts, they're kind of over an extended period of time. So I think for HBDU, we announced 10 years and induced, we've talked about that being a roughly 10 to 15 year program. We will see a little bit of front loading as we build up kind of the infrastructure investments on those in the early parts of the year. But generally speaking, they're pretty distributed over the life of the period of performance. So, you know, maybe a little bit waiting early, but certainly not significant. So, it'll be relatively distributed over those 10 or 10 to 15 years, depending on the contract that you're talking about. Those contracts are structured as fixed price programs. As you know, we typically will enter into kind of a base level margin percentage and then ultimately work to outperform those over a period of time. Our special materials business has had a long history of being able to outperform. And so, typically, we do not make any of those kind of large-scale adjustments from an EAC perspective until we're probably around 25% or more on the contract. So, I would expect that the kind of lower margin to last for the first couple years And then ultimately, you know, we would be highly focused on driving improvement in that EAC and being able to recognize a higher profit.

I appreciate that, caller, Mike. And then just Rex, just on Project Pele, could you just give us the latest update on how that's going? Because it sounds like you said delivery in 27. I thought that was – is that later than previously planned? Just give us any more updates there.

Yes, Peter, that is later than the contract originally called for. You know, that said, the requirements for that program have been evolving, particularly the role of the National Labs in that. And so it's not unexpected. And the program's doing very nicely. We are assembling the reactor core down in Lynchburg, Virginia, right now and do expect to deliver that reactor and that fuel to Idaho National Laboratory in 2027, and they'll fire it up and test it out there. So the program's going great.

Thanks, guys. Nice results. Thanks, Peter. Thanks, Peter.

Next question comes from the line of Jeffrey Campbell with Seaport. Your line is open.

First of all, congratulations on the strong quarter. Regarding DEUCE, the press release announcing the $1.5 billion award said that the pilot plant will demonstrate LEU production for defense missions before being repurposed to produce HEU for naval propulsion applications. To be clear, will the capabilities to produce HEU be accomplished in the current appropriation or will it require additional funding? So that initial tranche of funding is about licensing, Jeff, licensing and preparation for the high-enriched uranium cascade, which ultimately will be based at our fuel services business in Irwin, Tennessee. That combined with a centrifuge manufacturing development capability that we're doing up in Oak Ridge, Tennessee. So, that actually, the first tranche of funding does not relate to the production of the material itself.

Okay.

Yeah, thank you. And regarding the four new second-generation electromagnetic isosop separator units that you announced being commissioned by Connectrix, does the entirety of that 500-kilogram of uterbium output now belong, or will it belong, to BWXT Medical? And were there any noteworthy differences between the first and the second generation, the MIS units? Yeah, that's 500 grams of output. But the Euterium-176, which, of course, is the base material for Lutetium-177, so it's an important precursor for that nuclear medicine product.

There's no essential difference between this generation and the prior generation.

It's really just an increase in capacity of about 500%, by the way. So it's an impressive capability. We haven't integrated Conetrix medical business into PWXT's medical business for some good reasons. But those businesses are supporting one another, and we're finding strategic synergies there that are pretty powerful.

Okay, thank you.

You're welcome.

Next question comes from the line of Scott Duschel with Deutsche Bank. Your line is open.

Hey, good evening. Mike, could you slice up the chipset value of the Steam generator content you won with Rolls-Royce?

We haven't given specifics around that. I think, you know, Scott, when we talk about the SMR opportunity with Rolls, we've discussed, you know, in the $50 to $100 million range, I think we're, you know, squarely in the middle of that as it relates to the roles content. So we feel comfortable kind of being in that range from a roles perspective, but we haven't disclosed, you know, the specifics.

Okay. And then the press release announcing that one discussed a localization plan for future manufacturing work. I think most of what Rolls-Royce is currently bidding on is for reactors in Europe. So is the implication here that you may elect to build out a manufacturing footprint in Europe if the demand is there? Yeah, I think, Scott, we were evaluating that and other opportunities for localization. That seems to be the trend in commercial nuclear power. So we certainly are considering it. And then last question, sorry to be a pig, but Mike, can you walk us through the puts and takes on 2026 free cash flow that resulted in that guide to flat to slightly up? I heard some of the pieces in the script. I'm just curious if you could put a bow on it for us.

Yeah. Yeah, so I think, you know, we've seen a pretty significant step change over the last couple of years. As we mentioned in our investor day, our kind of medium-term outlook was to see, you know, continued kind of one day and call it cash conversion cycle days, which is the internal metric that we use. That's roughly about a 10 million improvement each year. We've seen a sizable improvement going from 23 to 24 and then from 24 to 25. You know, if you remember, we started the year at low into the range of $265. Now we're guiding to $285, approximately $425. So part of this is driven by some of these investments in the newer contracts. We are able to negotiate some milestones on DEUCE and HBDU that are hitting in the fourth quarter of $25, which is good. but it creates a step function as you look into next year in just the timing of when you get to that next milestone. And so that's a little bit of what we're seeing. In addition to that, you know, we do have, we're going to be on a little bit higher end of the range on CapEx. You know, we went up to 6% for this year. We'll be 5.5% to 6% of revenue for next year. So, you're seeing a little bit of, you know, capex as we continue to invest in our growth initiatives across the board. And so, when you kind of take a look at that, you're seeing that basically we're going to end up flat based on even though we'll have a probably one day working capital improvement, that's going to be offset by, call it 10 to 15 million of timing related to kind of milestones payments for some of these larger new contracts.

Thank you.

Next question comes from the line of Jeff Grampy with Northland Securities. Your line is open.

Evening, folks. Thanks for the time. I'm curious, when we look at this 26 outlook, what do you guys view as kind of the main risk to achieving that outlook? And then maybe this is more of a 25 discussion point, but does an extended government shutdown represent a risk at all to this year's or next year's outlook? Thanks.

Yeah, so I think I'll start with the second question, just on the government shutdown. And just, you know, to clarify that the majority of the impact of our government shutdown is specific to our technical services, part of the business within government operations where we run based, you know, different joint ventures with external partners to do M&O and other environmental cleanup on DOE sites. I think the teams have done a great job of managing funding. The majority of our sites are fully operational still at this point, and we're kind of making sure that we're continuing with the mission. I would say we have not contemplated a long-term shutdown in our guidance, and so to the extent that we're seeing an extended shutdown, I don't see that as a major driver for 2025, but I would say that that would create some risk if it extended into 26 for an extended period of time. As far as kind of the puts and takes from next year, I would say, yeah, from an opportunity perspective, we continue to focus on operational performance and OPEX initiatives, which we discussed a lot. But when you look at our kind of guidance for next year, we are still working through some of the old pricing agreements. I mentioned last quarter that, you know, I anticipated some of that to continue in through 2026. So to the extent that we can drive continued performance in the business and we're able to, you know, see that productivity, we could have some upside as it relates to opportunities in EAC potential write-ups. We have not assumed a substantial amount of EAC write-ups in our current guidance. In addition to that, you know, based on the timing of some of the new special materials contracts, we've seen, you know, earlier this year we had strong performance in those contracts. We'll continue to focus on performing well in that part of the business, and so that could result in, you know, ultimately some opportunities to the guidance that we've laid out. From a risk standpoint, I would say a lot of this relates to just kind of the overall timing of our commercial nuclear opportunities. You know, we're seeing a flurry of activity in RFP and RFIs, and we certainly have a decent visibility into when the timing of those orders are. But if you had some delays in the timing of those orders, it could have an impact or create some risk for next year. And then we always will highlight just, you know, defense spending. You know, we haven't seen a major impact on that, but that's always a potential risk. And, you know, I mentioned the extended government shutdown. That could be also a potential risk. So those are the big puts and takes.

Awesome. I appreciate that thorough answer. That's really helpful. And it kind of ties into my follow-up. So, Rex, you mentioned, you know, this demand market is being unprecedented. It seems like the last couple of quarters have been more headlined, more on the government segment of the business. I'm curious how you see the commercial side playing out, the potential acceleration there. I mean, it sounds like that the pipeline is robust. And so maybe is this something that you guys think kind of materializes or accelerates from a kind of order backlog standpoint over the coming quarters? Or do you have that level of conviction or insight at this point in the cycle?

No, I do think, Jeff, that we'll see that order start to accelerate. I think, you know, obviously the Westinghouse announcement was maybe the first domino to fall. If you look at small modular reactors, OPG seems committed to building out those four. We'll see what the next announcement for SMRs is in the U.S. I think that should be Tennessee Valley Authority or another nuclear utility. There's a lot of chatter about that. I do fully expect that nuclear utilities in Canada go forth with the large bills pretty soon. Like I said, we have task orders, contracts are ready to study the licensing for those can-do derivatives. And so, yeah, a lot of things are falling into place, a lot of announcements, a lot of demand. And so I think next year for this business will be more about commercial orders and commercial announcements than about government orders and announcements, which characterize 25.

Great. Thank you guys for the time. Appreciate it.

Next question comes from the line of Michael Charmoli with Trui Securities. Your line is open.

Hey, evening, guys. Thanks for taking the questions. Maybe, Rex, not to derail things, but maybe talk more about the, I guess, the boring portion of your business. No one's asked about Navy subs, shipbuilding, and just kind of general thoughts. Mike, I heard you talk about the CapEx. I think we still have a commitment to AUKUS out there, but any kind of general update on kind of what you're seeing in terms of, you know, VA, Columbia cadence, you know, how you're thinking about, you know, whether or not AUKUS close in at some point, do you need more CapEx or more capacity?

Yeah, thanks for the question, Mike. I think it's taking quite a positive turn here in the last quarter, our boring business in naval nuclear propulsion. You know, AUKUS had been in question because it's being examined by the Department of Defense, but you saw the sort of love fest between the Australian prime minister and the president. And it looks like AUKUS is absolutely going forward now. We're also seeing at the same time, we're seeing positive things at the shipyards at both GD and HII seem to be turning the corner on production. And I think that's quite a positive for all of us. And then, of course, there's that announcement, that surprise announcement about South Korea and the idea that the South Koreans have built a shipyard for nuclear-powered submarines in the U.S. Now, that thing is not well formed from my perspective, but we don't know what that looks like yet. But to the extent that the U.S. is involved in the nuclear propulsion system, that could be an interesting opportunity for us. And so I see a lot of upside in the business relative to a couple of quarters ago. We do need more capacity to meet the demand for the AUKUS program. And we do have CapEx projects that are underway with our customer and naval reactors for that purpose. So there's a bit of that going on already. So full steam ahead.

Got it. Got it. And then just one more, Mike, I think I've got this. I mean, the implied government EBITDA margins, you know, look to be down next year. Sounds like it's just the front end loading of some of that lower margin work and, you know, maybe even some of the other pilot progression projects. But is anything changing, you know, with that core Navy business, or is it really just kind of some lower-margin startup contracts that's weighing on the margins?

No, that's exactly right. You're, you know, if you look at 2026, most of it is mixed pressure. Half of the revenue growth is driven by Deuce and HBDU. And as we mentioned, we start off at a, you know, pretty low margin. and then would anticipate, you know, higher positive EACs in the future. I would say in addition to that, we are still dealing with a little bit of just the burn off of the pricing arrangements that we had entered into shortly before COVID, before we saw significant labor costs and those types of things. And so, as I mentioned before, that mix will start to change next year. And, you know, as we work through that and into the new pricing arrangements that we just recently entered into, so we're hopeful that we're going to focus on that. The other thing I would just say is we're highly focused on operational excellence initiatives, and we have a large focus on margin improvement that we're going to be driving into the business. And we continue to focus on that every day. So we'll continue to make investments to drive performance in the business, and hopefully we'll be able to outperform and see some positive EACs next year. Got it.

Next question comes from the line of Jed Dorsheimer with William Blair. Your line is open.

Hey, thanks for taking my question. And, yeah, I'll echo the other sentiments. Congratulations on a great quarter here, guys. I guess just first one, if I just kind of unpack the, you know, commercial growth, I noticed that you separated out the growth from Conetrix and specifically in your radiopharma business, you know, that supply with Novartis, it looks, you know, Plavicto got off label from pre-chemo, which expands. And so my question is, were you supply constrained in the quarter in terms of, you know, at the precursor or for the Letitia M-177? And, you know, previously you had talked about, I think, 30 plus phase three. So I'm just wondering how we should expect radiopharma growth and whether or not that was limited by the capacity.

Yeah, I don't. Hey, Jed, I don't think we were supply constrained for that product. You know, we're pretty far downstream. We do the base material, the uterbium-176 and lutetium-177. We don't produce the active pharmaceutical ingredient that goes to a customer upstream of us. but we know we don't feel we're not uh in a position of supply constraint for that product as to how that's going to grow i do expect lutetium growth to continue to accelerate i i can't predict that one for our business right now but uh but certainly there will there will be higher demand

in the future got it and then just sticking with commercial but switching to the uh reactor side And it sounds, you know, if you received an RFP for, you know, a Rolls SMR, for example, just as an example here, or even for, you know, an AP1000, you know, that would obviously drive the backlog, but wouldn't contribute anything to growth next year. Is that correct? I just wanted to make sure that it seems like that would be the case, but just wanted to confirm it. In other words, 26 is a year of, you know, RFBs, wins, and, you know, while most of the reactor side would be Bruce and OPG up in Canada, correct?

Yeah, that's correct.

Yeah, that's correct.

Yeah, we don't have a lot of that kind of scope in the forecast, if that's what you're asking. Yeah, that was one of those. Yeah, right. From my perspective, the growth numbers that we put out there for 26, those kind of early targets for growth, I don't see much. I mean, I frankly don't see much risk on the revenue side because we book so much business in naval reactors, special materials, and even on the commercial side and on the medical side. So it's a low-risk outlook from a standpoint of revenue. We just need to drive margins. But, yeah, anything that we would get on the commercial side, say, from the AP1000, be added to that.

Great.

Thanks, guys.

Thank you.

Next question comes from the line of Android Madrid with BTIG. Your line is open.

Rex, Mike, Chase, good afternoon. Good afternoon. could you maybe give us a status update on draco i know you said last quarter it kind of lives on through nasa but we did see you guys call out some weaker micro reactor volumes in the quarter and i

wanted to know if it was attributable to this yeah that's exactly right uh so the draco program devolved into you know single agency support it was it was darpa it was a darpa and nasa joint program. Now it's a NASA nuclear thermal propulsion program called Sentry, and the funding hasn't really shaped up for that in a meaningful way yet. We do have some task orders under that contract, and we're able to keep our team together, but it's a lower level of revenue, and it's hard to predict what the outcome of that will be. Certainly, NASA seems to be focused on lunar efficient surface power right now, and we've assembled a team to go attack that opportunity. But nuclear thermal propulsion is still in need on the civil space and national security side. So I do think that program goes forward in some form in the future. It's just hard to predict right now.

Got it. Got it. No, that makes sense. And Mike, I think you called it out earlier, but on the 80-bill nuclear partnership that was recently announced, I mean, what gains could be, you know, captured there, if any? I mean, how do we assess that opportunity for you guys, if it is an opportunity?

Yeah, I don't think – I mean, we haven't given specific guidance on what the size of that opportunity is at this point.

I'll just add to that that the opportunity there is for component manufacturing, which is obviously right in our sweet spot. So it could be, you know, steam generators, reactor pressure vessels, those kinds of things. And so I think the opportunity set is pretty interesting, but it's not specific yet.

Got it. Got it. I'll leave it there. Thanks, gentlemen.

Next question comes from the line of Ron Epstein with Bank of America. Your line is open.

Hi, good afternoon. This is Alex Preston on for Ron today. I was just curious on M&A, right? Obviously, talked through a couple times AOT and Conetrix performing really well. I'm curious if you could just walk us through a little bit about the environment you're seeing, any appetite going forward for more investments. It seems like you'll be well within your sort of two to three times leverage range going even until like the end of the year.

Yeah, but maybe I'll make a broad comment about that and then flip it over to Mike. We've been historically pretty picky about doing acquisitions because our philosophy there is to go and get things that amplify our strategic intentions in the nuclear space. And so I think that means you're necessarily limited on the number of targets. But that said, we did a couple of really good ones this year with Conetrix and AOT and we've done some very good ones in the past. Nordeon was a good acquisition for us. The GE Itachi assets in Canada, very good acquisition for us. I would say that we are interested in acquiring right now because as I said on the call, or as I said in one of the answers, we certainly can get assets within our multiple. So you've got an opportunity to create value there. So we're continuing to look. I think it's super interesting and we'll acquire if it matches what we're trying to do strategically. Otherwise, we'll stay away from it.

Yeah, and I think we feel comfortable where we are from a leverage standpoint. One of my priorities is to continue to clean up some of the balance sheet and create some capacity and dry powder to be opportunistic about acquisitions going forward.

I appreciate the color.

Next question comes from the line of Pete Skabitsky with Alembic Global. Your line is open.

Yeah, just a quick housekeeping question, I guess, for Mike. Mike, the $15 million step up in DNA in 2026, this is a small EBIT impact. But I was just wondering, does that relate to the two new contracts in government or is it, you know, from Tech99 or something completely different?

No, it's not related to either. Part of this is the timing difference between when we get recovery under, you know, cost accounting standards and financial accounting standards. but no major step changes that relates to Tech99. That won't happen until that program has gone through full approval. And then from the initial investments that we've been doing related to the new contracts, we're starting to spend that, but those aren't placed in service. So you're not going to see a significant step up of that in 26. It'll kind of bleed in over a period of time.

Got it. Okay. Thank you.

And our last question comes from the line of Scott Duschel with Deutsche Bank. Your line is open.

All right. I saved this question for the end of the call because it's probably where it belongs. But Rex, is rare earth handling or processing at all an area of strategic interest to the company, given your existing experience in the handling and processing of hazardous materials? So I don't think so, Scott. You know, our capabilities are around special nuclear materials and the materials handling and accountability systems that go with that.

We just aren't involved with rare earths typically,

I mean, apart from, you know, Euterbian 176, but just not in our playbook. And so I would say the answer to that is broadly no.

Okay, thank you.

That concludes the question and answer session. I would like to turn the call back over to Chase Jacobson for closing remarks.

Thank you, Desiree. Desiree, thank you, everybody, for joining us today. We appreciate your questions. We appreciate your interest in BWXT. We look forward to seeing many of you and speaking with you in the coming days and weeks and seeing you at investor events. If you have any questions, please reach out to me at investors at bwxt.com. Thank you.

Ladies and gentlemen, that concludes today's call. Thank you all for joining, and you may now disconnect.